Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High-Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial

Background

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients. The AVERT trial showed apixaban thromboprophylaxis reduced VTE in intermediate-to-high-risk patients initiating chemotherapy. However, the efficacy and safety of apixaban according to baseline chemotherapy class remain incompletely characterized.